Confronting the hypervariability of an immunodominant epitope eliciting virus neutralizing antibodies from the envelope glycoprotein of the human immunodeficiency virus type 1 (HIV-1).

PubWeight™: 0.82‹?›

🔗 View Article (PMID 1696353)

Published in Mol Immunol on June 01, 1990

Authors

A R Neurath1, N Strick

Author Affiliations

1: Lindsley F. Kimball Research Institute, New York Blood Center, NY 10021.

Articles by these authors

HIV-1 inhibition by a peptide. Nature (1993) 5.01

Identification and chemical synthesis of a host cell receptor binding site on hepatitis B virus. Cell (1986) 3.11

Hepatitis B virus contains pre-S gene-encoded domains. Nature (1985) 2.02

Antibodies to a synthetic peptide from the preS 120-145 region of the hepatitis B virus envelope are virus neutralizing. Vaccine (1986) 1.68

Location and chemical synthesis of a pre-S gene coded immunodominant epitope of hepatitis B virus. Science (1984) 1.63

Heavy chain subclass of human anti-platelet antibodies. Clin Immunol Immunopathol (1973) 1.61

Antibodies to synthetic peptides from the preS1 region of the hepatitis B virus (HBV) envelope (env) protein are virus-neutralizing and protective. Vaccine (1989) 1.61

Inhibition of HIV-1 infection by a fusion domain binding peptide from the HIV-1 envelope glycoprotein GP41. Biochem Biophys Res Commun (1993) 1.46

Specificity of antibodies elicited by a synthetic peptide having a sequence in common with a fragment of a virus protein, the hepatitis B surface antigen. Proc Natl Acad Sci U S A (1982) 1.33

Search for hepatitis B virus cell receptors reveals binding sites for interleukin 6 on the virus envelope protein. J Exp Med (1992) 1.32

Design of a "microbicide" for prevention of sexually transmitted diseases using "inactive" pharmaceutical excipients. Biologicals (1999) 1.30

Cellulose acetate phthalate, a common pharmaceutical excipient, inactivates HIV-1 and blocks the coreceptor binding site on the virus envelope glycoprotein gp120. BMC Infect Dis (2001) 1.21

Bovine beta-lactoglobulin modified by 3-hydroxyphthalic anhydride blocks the CD4 cell receptor for HIV. Nat Med (1996) 1.20

B cell epitope mapping of human immunodeficiency virus envelope glycoproteins with long (19- to 36-residue) synthetic peptides. J Gen Virol (1990) 1.15

Anti-human immunodeficiency virus type 1 microbicide cellulose acetate 1,2-benzenedicarboxylate in a human in vitro model of vaginal inflammation. Antimicrob Agents Chemother (2005) 1.13

Radioimmunoassay for albumin-binding sites associated with HBsAg: correlation of results with the presence of e-antigen in serum. Intervirology (1979) 1.08

Synthetic peptides and anti-peptide antibodies as probes to study interdomain interactions involved in virus assembly: the envelope of the human immunodeficiency virus (HIV-1). Virology (1992) 1.06

Host specificity of a serum marker for hepatitis B: evidence that "e antigen" has the properties of an immunoglobulin. Proc Natl Acad Sci U S A (1977) 1.06

Genetic restriction of immune responsiveness to synthetic peptides corresponding to sequences in the pre-S region of the hepatitis B virus (HBV) envelope gene. J Med Virol (1985) 1.05

Cumulative experience in the detection of antiplatelet antibody in 234 patients with idiopathic thrombocytopenic purpura, systemic lupus erythematosus and other clinical disorders. Am J Med (1972) 1.03

Two partially overlapping antiviral peptides from the external portion of HIV type 1 glycoprotein 41, adjoining the transmembrane region, affect the glycoprotein 41 fusion domain. AIDS Res Hum Retroviruses (1995) 1.00

Detection of receptors for hepatitis B virus on cells of extrahepatic origin. Virology (1990) 1.00

Prevalence of hepatitis B "e" antigen and its antibody in various HBsAg carrier populations. Am J Epidemiol (1981) 0.98

Multifaceted consequences of anti-gp41 monoclonal antibody 2F5 binding to HIV type 1 virions. AIDS Res Hum Retroviruses (1995) 0.98

Association of hepatitis B e-antigen (HBeAg) determinants with the core of Dane particles. J Gen Virol (1979) 0.97

Three-dimensional structure-activity analysis of a series of porphyrin derivatives with anti-HIV-1 activity targeted to the V3 loop of the gp120 envelope glycoprotein of the human immunodeficiency virus type 1. J Med Chem (1994) 0.97

e/anti-e in hepatitis B, an antibody/anti-antibody system. Lancet (1977) 0.96

Radioimmunoassays of hidden viral antigens. Proc Natl Acad Sci U S A (1982) 0.95

Detection of splenic anti-platelet antibody synthesis in idiopathic autoimmune thrombocytopenic purpura (ATP). Br J Haematol (1972) 0.95

Search for epitope-specific antibody responses to the human immunodeficiency virus (HIV-1) envelope glycoproteins signifying resistance to disease development. AIDS Res Hum Retroviruses (1990) 0.95

The putative cell receptors for hepatitis B virus (HBV), annexin V, and apolipoprotein H, bind to lipid components of HBV. Virology (1994) 0.92

Characterization of monoclonal antibodies specific for the pre-S2 region of the hepatitis B virus envelope protein. Mol Immunol (1986) 0.90

Quantitation of cellulose acetate phthalate in biological fluids as a complex with ruthenium red. Anal Biochem (2001) 0.90

Cells transfected with human interleukin 6 cDNA acquire binding sites for the hepatitis B virus envelope protein. J Exp Med (1992) 0.89

Chemically modified bovine beta-lactoglobulin blocks uptake of HIV-1 by colon- and cervix-derived epithelial cell lines. J Acquir Immune Defic Syndr Hum Retrovirol (1996) 0.89

Blocking of CD4 cell receptors for the human immunodeficiency virus type 1 (HIV-1) by chemically modified bovine milk proteins: potential for AIDS prophylaxis. J Mol Recognit (1996) 0.87

Inhibitory activity of monoclonal antibody F35.25 on the interaction between hepatocytes (HepG2 cells) and preS1-specific ligands. Mol Immunol (1991) 0.87

Enzyme-linked fluorescence immunoassays using beta-galactosidase and antibodies covalently bound to polystyrene plates. J Virol Methods (1981) 0.87

3-Hydroxyphthaloyl beta-lactoglobulin. III. Antiviral activity against herpesviruses. Antivir Chem Chemother (1998) 0.87

Antigenic mimicry of an immunoglobulin A epitope by a hepatitis B virus cell attachment site. Virology (1990) 0.86

Some properties of hepatitis B core antigen isolated from serum of infected humans. J Gen Virol (1978) 0.84

Expression in Escherichia coli of a cloned DNA sequence encoding the pre-S2 region of hepatitis B virus. Proc Natl Acad Sci U S A (1985) 0.84

Radioimmunoassay and enzyme-linked immunoassay of antibodies to the core protein (P24) of human T-lymphotropic virus (HTLV III). J Virol Methods (1985) 0.83

Localization of a hepatitis B surface antigen determinant deduced from results of chemical modifications. J Virol Methods (1981) 0.83

Antibodies to synthetic peptides from the pre-S1 and pre-S2 regions of one subtype of the hepatitis B virus (HBV) envelope protein recognize all HBV subtypes. Mol Immunol (1987) 0.83

Detection of antiviral antibodies with predetermined specificity using synthetic peptide--beta-lactamase conjugates: application to antibodies specific for the preS region of the hepatitis B virus envelope proteins. J Gen Virol (1986) 0.83

Structural requirements for and consequences of an antiviral porphyrin binding to the V3 loop of the human immunodeficiency virus (HIV-1) envelope glycoprotein gp120. J Mol Recognit (1997) 0.82

Heterogeneity of human platelets. V. Differences in glycolytic and related enzymes with possible relation to platelet age. J Clin Invest (1972) 0.82

Toleration of amino acid substitutions within hepatitis B virus envelope protein epitopes established by peptide replacement set analysis. II. Region S(122-136). Pept Res (1992) 0.82

Confirmatory evidence for the association of hepatitis B surface antigen with antigenic determinants reactive with antibodies present in some anti-HBe-positive sera. J Gen Virol (1980) 0.81

Toleration of amino acid substitutions within hepatitis B virus envelope protein epitopes established by peptide replacement set analysis. I. Region S(139-147). Pept Res (1992) 0.81

Radioimmunoassay and some properties of human antibodies to hepatitis B core antigen. J Gen Virol (1978) 0.81

Improbability of harmful autoimmune responses resulting from immunization with HIV-1 envelope glycoproteins. AIDS Res Hum Retroviruses (1993) 0.80

Enzyme-linked immunoassay of pre-S gene-coded sequences in hepatitis B vaccines. J Virol Methods (1985) 0.80

Properties of delipidated hepatitis B surface antigen (HBsAg) and preparation of its proteolytic cleavage fragments carrying HBsAg-specific antigenic determinants. Intervirology (1978) 0.80

Radioimmunoassay of hepatitis B e-antigen (HBeAg): identification of HBeAg not associated with immunoglobulins. J Gen Virol (1979) 0.80

Antigenic sites related to human serum proteins in HBsAg: isolation from normal human serum of a high-molecular-weight glycoprotein reacting with antialbumin. J Med Virol (1978) 0.79

Antibodies as immunological probes for studying the denaturation of HBsAg. J Med Virol (1981) 0.78

Antibodies to hepatitis B surface antigen (HBsAg) elicited by immunization with a synthetic peptide covalently linked to liposomes. J Gen Virol (1984) 0.78

Automated enzyme-linked fluorescence immunoassays for antiviral antibodies: a test for anti-HBs. J Virol Methods (1982) 0.78

Antibodies recognizing human serum albumin are not elicited by immunization with preS2 sequences of the hepatitis B virus envelope protein. J Med Virol (1988) 0.78

Antibody responses of chimpanzees immunized with synthetic peptides corresponding to full-length V3 hypervariable loops of HIV-1 envelope glycoproteins. AIDS Res Hum Retroviruses (1991) 0.78

H-2 linked genetic control of immune responsiveness to hepatitis B surface antigen (HBsAg) in mice. J Med Virol (1983) 0.78

Peptides mimicking selected disulfide loops in HIV-1 gp120, other than V3, do not elicit virus-neutralizing antibodies. AIDS Res Hum Retroviruses (1991) 0.78

125I-labeled anti-2,4-dinitrophenyl (DNP)-antibodies: a universal reagent for solid phase radioimmunoassays. Mol Immunol (1979) 0.77

An antigen detected frequently in human sera with elevated levels of alanine aminotransferase: a potential marker for non-A, non-B hepatitis. J Gen Virol (1980) 0.77

Immunological cross-reactivity between preS2 sequences of the hepatitis B virus envelope proteins corresponding to serological subtypes adw2 and ayw. Mol Immunol (1987) 0.76

Strategies for detection of transfusion-transmitted viruses eluding identification by conventional serologic tests. II. Detection of host DNA in human plasmas with elevated alanine aminotransferase. J Virol Methods (1984) 0.76

Glycodelins GdA and GdS modified by 3-hydroxyphthalic anhydride inhibit gp120-CD4 binding and HIV-1 infection in vitro. Lab Invest (1997) 0.75

Radioimmunoassays of hidden viral antigens. Dev Biol Stand (1983) 0.75

Affinity chromatography of hepatitis B surface antigen from e-antigen-positive sera on insolubilized cross-linked albumin. Brief report. Arch Virol (1979) 0.75

Antibody response to two synthetic peptides corresponding to residues 45-68 and 69-79 of the major protein of hepatitis B surface antigen. Virus Res (1984) 0.75

Monoclonal antibodies to hepatitis B surface antigen (HBsAg) with anti-alpha specificity recognize a synthetic peptide analogue (S135-155) with unmodified lysine (141). J Virol Methods (1984) 0.75

Advances in understanding structure-function relationships in hepatitis B virus (HBV) envelope (ENV) proteins. Adv Exp Med Biol (1989) 0.75

Evidence against the postulated identity of e-antigen with DNA polymerase associated with the hepatitis B candidate virus. Intervirology (1976) 0.75

Strategies for detection of transfusion-transmitted viruses eluding identification by conventional serologic tests. I. Radioimmunoassay for picogram quantities of DNA. J Virol Methods (1983) 0.75

Anti-e and rheumatoid factor. Lancet (1977) 0.75

Radioimmunoassay and enzyme-linked immunoassay of antibodies directed against lymphadenopathy-associated virus (LAV) proteins larger than the core protein (P24). J Virol Methods (1985) 0.75

Confronting the hypervariability of an immunodominant epitope eliciting virus neutralizing antibodies from the envelope glycoprotein of the human immunodeficiency virus type 1 (HIV-1)--II. Synthetic peptides linked to HIV-1 carrier proteins gag and nef. Mol Immunol (1991) 0.75

Hepatitis B virus surface antigen (HBsAg) as carrier for synthetic peptides having an attached hydrophobic tail. Mol Immunol (1989) 0.75

Specificity of antibodies elicited by a synthetic peptide having a sequence in common with a fragment of a virus protein--the hepatitis B surface antigen. Dev Biol Stand (1983) 0.75

Discovery of a cytoplasmic-dominant alloantigen prevalent in erythrocytes. Vox Sang (1981) 0.75

Radioimmunoassay of human beta interferon. J Interferon Res (1982) 0.75

A herpesvirus inhibitor from bovine whey. Lancet (1996) 0.75

Toleration of amino acid substitutions within hepatitis B virus envelope protein epitopes established by peptide replacement set analysis. I. Region S(139-147). Pept Res (1992) 0.75

Delineation of contiguous determinants essential for biological functions of the pre-S sequence of the hepatitis B virus envelope protein: its antigenicity, immunogenicity and cell-receptor recognition. Ann Inst Pasteur Virol (1989) 0.75